Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial

Journal of Alzheimer's Disease

Volumn 52, Issue 1, 2016, Pages 345-357

  Homma, Akira ^a   Atarashi, Hirotsugu ^b   Kubota, Naoki ^c   Nakai, Kenya ^c   Takase, Takao ^c  

^a Tokyo Dementia Care Research and Training Center   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c EISAI CO LTD   (Japan)

Author keywords

Alzheimer's disease; cholinesterase inhibitors; donepezil; double blind study; Japan

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; DELAYED RELEASE FORMULATION; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY WEIGHT; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CONTUSION; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; OPTIMAL DRUG DOSE; PARALLEL DESIGN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SUBARACHNOID HEMORRHAGE; SUSTAINED DRUG RELEASE; URINARY TRACT INFECTION; VOMITING; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; JAPAN; MENTAL HEALTH; OUTPATIENT; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; JAPAN; MALE; MENTAL STATUS SCHEDULE; NOOTROPIC AGENTS; OUTPATIENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84973140731     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151149     Document Type: Article

References (15)

1. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366, 893-903
2. Atri A, Hendrix SB, Pejović V, Hofbauer RK, Edwards J, Molinuevo JL, Graham SM (2015) Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: A pooled area under the curve analysis. Alzheimers Res Ther 7, 28
3. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T (2008) Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 25, 399-407
4. Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) Spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135
5. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N (1996) Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implication for research and treatment. Int Psychogeriatr 8(Suppl 3), 497-500
6. Kaasinen V, Nagren K, Järvenpää T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO (2002) Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 22, 615-620
7. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A (2010) Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther 32, 1234-1251
8. Schmitt FA, AshfordW, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ (1997) The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11, S51-S56
9. Joffres C, Graham J, Rockwood K (2000) Qualitative analysis of the clinician interview-based impression of change (Plus): Methodological issues and implications for clinical research. Int Psychogeriatr 12, 403-413
10. Schneider LS, Olin JT (1996) Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr 8, 277-288
11. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48, 391-395
12. US Food and Drug Administration (2010) Clinical Pharmacology Biopharmaceutics Review(s). Drug Approval Package. http://www.accessdata.fda.gov/drugsatfda docs/ nda/2010/022568Orig1s000ClinPharmR.pdf. Posted 1 December 2010, Accessed 3 January 2016
13. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R (2013) Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: Analysis of effects of baseline features on treatment response. BMC Geriatr 13, 56
14. Han SH, Lee JH, Kubota N, Dash A (2014) Efficacy and tolerability of donepezil 23 mg/d versus donepezil 10 mg/d in patients with moderate to severe AD in an Asian population: Study 326 subanalysis. Alzheimers Dement 10, 450-451
15. Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A (2011) Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology 11, 57